Astria Therapeutics (ATXS) Operating Income: 2017-2018
Historic Operating Income for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to -$6.1 million.
- Astria Therapeutics' Operating Income fell 10.75% to -$6.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$26.4 million, marking a year-over-year increase of 2.79%. This contributed to the annual value of -$26.4 million for FY2018, which is 2.67% up from last year.
- Astria Therapeutics' Operating Income amounted to -$6.1 million in Q4 2018, which was down 1.33% from -$6.0 million recorded in Q3 2018.
- In the past 5 years, Astria Therapeutics' Operating Income registered a high of -$5.5 million during Q4 2017, and its lowest value of -$7.8 million during Q1 2017.
- For the 2-year period, Astria Therapeutics' Operating Income averaged around -$6.7 million, with its median value being -$6.8 million (2017).
- Data for Astria Therapeutics' Operating Income shows a peak YoY increase of 13.58% (in 2018) and a maximum YoY decrease of 10.75% (in 2018) over the last 5 years.
- Quarterly analysis of 2 years shows Astria Therapeutics' Operating Income stood at -$5.5 million in 2017, then decreased by 10.75% to -$6.1 million in 2018.
- Its Operating Income was -$6.1 million in Q4 2018, compared to -$6.0 million in Q3 2018 and -$6.6 million in Q2 2018.